Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ina, Y.
Right arrow Articles by Sato, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ina, Y.
Right arrow Articles by Sato, S.

Chest, Vol 105, 1179-1183, Copyright © 1994 by American College of Chest Physicians

ARTICLES

Antiphospholipid antibodies. A prognostic factor in sarcoidosis?

Y Ina, K Takada, M Yamamoto, T Sato, S Ito and S Sato
Second Department of Internal Medicine, Nagoya City University Medical School, Japan.

Serum antibodies against five types of phospholipids, antiphospholipid antibodies (aPL), were determined by an enzyme-linked immunosorbent assay in 55 patients with sarcoidosis. Either IgG or IgM aPL were detected in 21 patients (38 percent). This positive rate was significantly higher than that (7 percent) of healthy control subjects (p < 0.001). In terms of immunoglobulin classes, 5 cases had IgG aPL only, 11 cases had IgM aPL only, and 5 cases had both classes of aPL. No correlation was observed between the occurrence of aPL and disease activity of sarcoidosis. A significant correlation was noted between the occurrence of aPL and many extrathoracic organ lesions or the persistence of abnormal chest x-ray film findings for periods of 2 and 5 years. Taken together, the presence of aPL in sarcoidosis is a useful index to judge the prolongation of the disease.


This article has been cited by other articles:


Home page
 LupusHome page
R Singh, M D Conway, and W A Wilson
Antiphospholipid syndrome in a patient with sarcoidosis: a case report
Lupus, November 1, 2002; 11(11): 756 - 758.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
A. M.F. Yee and M. B. Pochapin
Treatment of Complicated Sarcoidosis with Infliximab Anti-Tumor Necrosis Factor-{alpha} Therapy
Ann Intern Med, July 3, 2001; 135(1): 27 - 31.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
J.-L. Dumas, D. Valeyre, C. Chapelon-Abric, C. Belin, J.-C. Piette, H. Tandjaoui-Lambiotte, M. Brauner, and D. Goldlust
Central Nervous System Sarcoidosis: Follow-up at MR Imaging during Steroid Therapy
Radiology, February 1, 2000; 214(2): 411 - 420.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by the American College of Chest Physicians.